Pharmafile Logo
Pharmafocus logo
Advanced Search

Human Genome Sciences

Showing 6 posts of 6 posts found.

Human Genome Sciences image

Glaxo seals $3 billion acquisition of HGS

July 17, 2012
Business Services, Research and Development, Sales and Marketing Benlysta, GSK, Human Genome Sciences, R&D

GlaxoSmithKline has finally sealed the acquisition of Human Genome Sciences, the company with which it co-markets lupus treatment Benlysta.  The …

News
GSK

GSK’s bid for Human Genome Sciences rejected

April 19, 2012
Sales and Marketing Benlysta, GSK, Human Genome Sciences, mergers and acquisitions

GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the …

News
systemic lupus erythematosus (SLE)

US approval for GSK’s lupus treatment Benlysta

March 10, 2011
Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus

GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …

News

Novartis drops two drug candidates, takes $600 million hit

October 6, 2010
Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis

Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …

News

Lonza wins two biologic contracts

July 16, 2010
Manufacturing and Production Elusys, Human Genome Sciences, Lonza

Swiss fine chemicals firm Lonza has secured two new contracts for its contract manufacturing division for monoclonal antibodies to treat …

News

EU regulators to assess potential lupus breakthrough drug

June 8, 2010
Sales and Marketing Benlysta, Human Genome Sciences, Lupus

GlaxoSmithKline and Human Genome Sciences have submitted a marketing application to the European Medicines Agency for their new lupus drug. …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024